ProQR Therapeutics (PRQR) Short Interest Ratio & Short Volume $3.60 -0.07 (-1.91%) (As of 10:27 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ProQR Therapeutics Short Interest DataProQR Therapeutics (PRQR) has a short interest of 677,600 shares. This marks a 408.33% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.5, indicating that it would take 0.5 days of the average trading volume of 524,910 shares to cover all short positions.Current Short Interest677,600 sharesPrevious Short Interest133,300 sharesChange Vs. Previous Month+408.33%Dollar Volume Sold Short$2.37 millionShort Interest Ratio0.5 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares81,680,000 sharesPercentage of Shares Shorted0.83%Today's Trading Volume27,304 sharesAverage Trading Volume524,910 sharesToday's Volume Vs. Average5% Short Selling ProQR Therapeutics? Sign up to receive the latest short interest report for ProQR Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPRQR Short Interest Over TimePRQR Days to Cover Over TimePRQR Percentage of Float Shorted Over Time Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. ProQR Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/2024677,600 shares $2.37 million +408.3%N/A0.5 $3.50 10/15/2024133,300 shares $241,273.00 -10.5%0.3%0.1 $1.81 9/30/2024148,900 shares $270,998.00 -6.2%0.3%1.1 $1.82 9/15/2024158,700 shares $293,595.00 -4.3%0.3%1.5 $1.85 8/31/2024165,900 shares $335,118.00 -4.5%0.3%1.5 $2.02 8/15/2024173,700 shares $387,351.00 +6.9%0.3%1.5 $2.23 Get the Latest News and Ratings for PRQR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/2024162,500 shares $313,625.00 -5.4%0.3%1.7 $1.93 7/15/2024171,700 shares $300,475.00 -0.9%0.3%1.7 $1.75 6/30/2024173,200 shares $287,512.00 -11.9%0.3%1.5 $1.66 6/15/2024196,600 shares $346,016.00 -18.5%0.4%1.6 $1.76 5/31/2024241,200 shares $470,340.00 +3.7%0.5%1.7 $1.95 5/15/2024232,500 shares $444,075.00 +8.0%0.5%1.5 $1.91 4/30/2024215,300 shares $417,682.00 -10.9%0.4%1.1 $1.94 4/15/2024241,500 shares $493,867.50 -7.5%0.5%1.2 $2.05 3/31/2024261,100 shares $597,892.89 -4.0%0.5%0.9 $2.29 3/15/2024272,100 shares $696,576.00 +3.1%0.5%0.9 $2.56 2/29/2024263,900 shares $533,078.00 -17.3%0.6%0.9 $2.02 2/15/2024319,000 shares $622,050.00 +5.9%0.7%1 $1.95 1/31/2024301,300 shares $653,821.00 -39.1%0.6%0.9 $2.17 1/15/2024494,800 shares $1.10 million -27.3%1.0%1.6 $2.23 12/31/2023680,400 shares $1.35 million -30.7%1.4%3.3 $1.98 12/15/2023981,100 shares $2.11 million +55.8%2.0%4.3 $2.15 11/30/2023629,800 shares $976,190.00 +2.6%1.3%2.9 $1.55 11/15/2023613,600 shares $908,128.00 -9.0%1.2%3.5 $1.48 10/31/2023674,200 shares $775,330.00 -4.5%1.4%3.8 $1.15 10/15/2023705,800 shares $868,134.00 +2.9%1.4%3.7 $1.23 9/30/2023685,900 shares $891,670.00 -24.4%1.4%3.3 $1.30 9/15/2023907,500 shares $1.46 million -3.6%1.8%4.7 $1.61 8/31/2023940,900 shares $1.51 million -2.9%1.7%3.9 $1.61 8/15/2023969,400 shares $1.49 million -16.4%1.8%3.5 $1.54 7/31/20231,160,000 shares $1.74 million +148.1%2.1%3.6 $1.50 7/15/2023467,600 shares $818,300.00 -2.9%0.9%1.3 $1.75 6/30/2023481,300 shares $779,706.00 -8.4%0.9%1.2 $1.62 6/15/2023525,200 shares $892,840.00 -34.0%0.9%0.8 $1.70 5/31/2023796,200 shares $1.39 million -41.9%1.4%1 $1.74 5/15/20231,370,000 shares $2.63 million -33.5%2.5%1.6 $1.92 4/30/20232,060,000 shares $4.49 million -20.2%3.7%2.3 $2.18 4/15/20232,580,000 shares $5.75 million -4.1%4.6%2.6 $2.23 3/31/20232,690,000 shares $5.73 million +66.1%5.1%2.2 $2.13 3/15/20231,620,000 shares $5.02 million +21.8%3.5%0.6 $3.10Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 2/28/20231,330,000 shares $3.92 million +16.7%2.9%0.5 $2.95 2/15/20231,140,000 shares $3.28 million -23.0%2.5%0.4 $2.88 1/31/20231,480,000 shares $4.08 million -20.0%3.1%0.5 $2.76 1/15/20231,850,000 shares $6.35 million -7.5%3.9%0.6 $3.43 12/30/20222,000,000 shares $7.40 million +102.0%4.2%0.8 $3.70 12/15/2022990,200 shares $1.64 million +0.1%1.7%0.4 $1.66 11/30/2022989,600 shares $1.22 million +44.3%1.7%1.3 $1.23 11/15/2022685,700 shares $654,980.64 -34.7%1.2%1 $0.96 10/31/20221,050,000 shares $971,355.00 -16.0%1.8%1.9 $0.93 10/15/20221,250,000 shares $1.11 million +131.4%2.2%2.6 $0.89 9/30/2022540,300 shares $401,983.20 +54.6%0.9%1.2 $0.74 9/15/2022349,600 shares $276,114.08 +1.7%0.6%0.9 $0.79 8/31/2022343,900 shares $271,646.61 +6.7%0.6%0.8 $0.79 8/15/2022322,300 shares $286,847.00 +3.2%0.6%0.7 $0.89 7/31/2022312,300 shares $261,582.48 -7.1%0.6%0.6 $0.84 7/15/2022336,000 shares $268,800.00 -52.0%0.6%0.5 $0.80 6/30/2022699,900 shares $544,522.20 +33.5%1.2%0.8 $0.78 6/15/2022524,400 shares $399,120.84 -27.4%1.0%0.5 $0.76 5/31/2022722,500 shares $476,850.00 -29.9%1.3%0.7 $0.66 5/15/20221,030,000 shares $638,600.00 -10.4%1.9%0.9 $0.62 4/30/20221,150,000 shares $796,950.00 -28.1%2.1%0.6 $0.69 4/15/20221,600,000 shares $1.26 million +27.0%2.9%0.8 $0.79 3/31/20221,260,000 shares $1.14 million -8.7%2.3%0.7 $0.91 3/15/20221,380,000 shares $1.28 million -31.7%2.5%0.8 $0.93 2/28/20222,020,000 shares $2.16 million -37.5%3.7%1.3 $1.07 2/15/20223,230,000 shares $4.07 million +46.2%5.9%2.2 $1.26 1/31/20222,210,000 shares $12.04 million +82.6%3.9%4.7 $5.45 1/15/20221,210,000 shares $8.18 million +45.2%2.5%3.2 $6.76 12/31/2021833,400 shares $6.68 million +23.7%1.7%2.5 $8.01 12/15/2021673,600 shares $4.75 million +6.4%1.4%1.6 $7.05 11/30/2021633,300 shares $4.47 million -35.5%1.3%0.9 $7.06 11/15/2021981,200 shares $7.61 million -41.9%2.0%1.4 $7.76 10/29/20211,690,000 shares $13.05 million -13.3%3.4%2.4 $7.72 10/15/20211,950,000 shares $15.37 million +8.3%3.9%2.6 $7.88 9/30/20211,800,000 shares $15.07 million -2.7%3.6%2.4 $8.37 9/15/20211,850,000 shares $15.30 million -12.3%3.7%2.7 $8.27 8/31/20212,110,000 shares $14.09 million -9.8%4.0%3.1 $6.68 8/13/20212,340,000 shares $14.72 million +29.3%4.4%4.8 $6.29 7/30/20211,810,000 shares $9.47 million -0.6%3.2%3.6 $5.23 7/15/20211,820,000 shares $10.06 million -4.2%3.4%3.5 $5.53 6/30/20211,900,000 shares $12.81 million +14.5%3.5%3 $6.74 6/15/20211,660,000 shares $12.32 million -15.3%3.1%0.5 $7.42 5/28/20211,960,000 shares $12.23 million -23.7%3.6%0.6 $6.24 5/14/20212,570,000 shares $16.19 million +62.7%N/A0.8 $6.30 4/30/20211,580,000 shares $10.13 million -23.3%N/A0.5 $6.41 4/15/20212,060,000 shares $13.02 million -21.1%N/A0.6 $6.32 3/31/20212,610,000 shares $18.61 million +125.0%N/A0.7 $7.13 3/15/20211,160,000 shares $5.75 million +29.0%N/A1.6 $4.96 2/26/2021899,400 shares $4.09 million -1.3%N/A1.3 $4.55 2/12/2021910,900 shares $4.58 million +4.6%N/A1.4 $5.03Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 1/29/2021870,800 shares $4.20 million -21.6%N/A1.4 $4.82 1/15/20211,110,000 shares $4.98 million +84.2%N/A2.1 $4.49 12/31/2020602,500 shares $2.51 million -39.1%N/A1.9 $4.17 12/15/2020988,700 shares $4.25 million -16.2%N/A3.3 $4.30 11/30/20201,180,000 shares $4.85 million +45.8%N/A4.7 $4.11 11/15/2020809,200 shares $3.29 million +14.9%N/A3.5 $4.07 10/30/2020704,200 shares $2.69 million +3.7%N/A4.2 $3.82 10/15/2020678,900 shares $3.10 million +2.7%N/A4.1 $4.56 9/30/2020661,100 shares $3.17 million -2.2%N/A4.6 $4.79 9/15/2020676,000 shares $3.56 million -1.7%N/A4.6 $5.27 8/31/2020687,800 shares $4.33 million +0.1%N/A4.5 $6.30 8/14/2020687,000 shares $3.62 million +1.5%N/A4.6 $5.27 7/31/2020676,600 shares $3.50 million +4.6%N/A4.5 $5.17 7/15/2020646,900 shares $3.18 million +2.9%N/A4.2 $4.92 6/30/2020628,500 shares $3.82 million +58.3%N/A4.2 $6.08 6/15/2020397,100 shares $2.08 million +4.2%N/A2.2 $5.25 5/29/2020381,200 shares $2.12 million -21.6%N/A2 $5.56 5/15/2020486,000 shares $2.50 million -9.9%N/A2.4 $5.14 4/30/2020539,100 shares $2.66 million -6.2%N/A2.5 $4.93 4/15/2020575,000 shares $2.86 million -7.0%N/A2.6 $4.97 3/31/2020618,000 shares $3.28 million -10.3%N/A2.7 $5.31 3/13/2020688,800 shares $3.30 million +17.6%2.5%3.5 $4.79 2/28/2020585,800 shares $3.29 million -1.8%2.1%2.5 $5.61 2/14/2020596,300 shares $4.33 million -18.2%N/A2.1 $7.26 1/31/2020729,000 shares $5.44 million -0.3%N/A2.5 $7.46 1/15/2020730,900 shares $6.21 million -31.1%N/A2.5 $8.49 12/31/20191,060,000 shares $8.75 million +8.2%N/A3.2 $8.25 PRQR Short Interest - Frequently Asked Questions What is ProQR Therapeutics' current short interest? Short interest is the volume of ProQR Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 677,600 shares of PRQR short. Learn More on ProQR Therapeutics' current short interest. Is ProQR Therapeutics' short interest increasing or decreasing? ProQR Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totaling 677,600 shares, an increase of 408.3% from the previous total of 133,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ProQR Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ProQR Therapeutics: Calliditas Therapeutics AB (publ) (0.01%), Arcutis Biotherapeutics, Inc. (23.72%), Rocket Pharmaceuticals, Inc. (13.05%), Mesoblast Limited (1.22%), ANI Pharmaceuticals, Inc. (10.27%), Ardelyx, Inc. (10.16%), Applied Therapeutics, Inc. (10.43%), Avadel Pharmaceuticals plc (9.82%), Cogent Biosciences, Inc. (7.63%), Bicycle Therapeutics plc (6.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short ProQR Therapeutics stock? Short selling PRQR is an investing strategy that aims to generate trading profit from ProQR Therapeutics as its price is falling. PRQR shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ProQR Therapeutics? A short squeeze for ProQR Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRQR, which in turn drives the price of the stock up even further. How often is ProQR Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRQR, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies ANIP Short Interest RCKT Short Interest ARDX Short Interest GYRE Short Interest MESO Short Interest APLT Short Interest AVDL Short Interest COGT Short Interest COLL Short Interest BCYC Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PRQR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
